These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27289250)

  • 1. Assessing analytical comparability of biosimilars: GCSF as a case study.
    Nupur N; Singh SK; Narula G; Rathore AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():165-171. PubMed ID: 27289250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing analytical comparability for "biosimilars": filgrastim as a case study.
    Rathore AS; Bhambure R
    Anal Bioanal Chem; 2014 Oct; 406(26):6569-76. PubMed ID: 24866713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product.
    Sörgel F; Lerch H; Lauber T
    BioDrugs; 2010 Dec; 24(6):347-57. PubMed ID: 20873878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Structural, Biological, and Functional Similarity of Biosimilar Granulocyte Colony Stimulating Factor to its Reference Product.
    Bor Tekdemir Z; Seckin AI; Kacar T; Yilmaz E; Bekiroglu S
    Pharm Res; 2020 Oct; 37(11):215. PubMed ID: 33026512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
    Cerutti ML; Pesce A; Bès C; Seigelchifer M
    BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product.
    Halim LA; Márquez M; Maas-Bakker RF; Castañeda-Hernández G; Jiskoot W; Schellekens H
    Pharm Res; 2018 Oct; 35(11):226. PubMed ID: 30280277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.
    Chen L; Wang L; Shion H; Yu C; Yu YQ; Zhu L; Li M; Chen W; Gao K
    MAbs; 2016 Oct; 8(7):1210-1223. PubMed ID: 27380163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
    Joshi S; Rathore AS
    BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
    Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
    BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
    Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
    BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.
    Nupur N; Chhabra N; Dash R; Rathore AS
    MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study.
    Bhattacharya S; Rathore AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123896. PubMed ID: 37776677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytic characterization of biosimilars.
    Sullivan PM; DiGrazia LM
    Am J Health Syst Pharm; 2017 Apr; 74(8):568-579. PubMed ID: 28389456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.
    Cho IH; Lee N; Song D; Jung SY; Bou-Assaf G; Sosic Z; Zhang W; Lyubarskaya Y
    MAbs; 2016; 8(6):1136-55. PubMed ID: 27246928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP
    Jeong YR; Jeong RU; Son JH; Kwon JC; Jung S; Song MA; Hwang JA; Lee GM
    BioDrugs; 2018 Apr; 32(2):153-168. PubMed ID: 29556960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromatographic and electrophoretic assessment of Filgrastim biosimilars in pharmaceutical formulations.
    Shaltout EL; Al-Ghobashy MA; Fathalla FA; Salem MY
    J Pharm Biomed Anal; 2014 Aug; 97():72-80. PubMed ID: 24816160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National Control Laboratory Assessment of Quality of Rituximab Biosimilars in India.
    Mishra NN; Sharma A; Shalini S; Sharma S; Jain P; Sharma RK; Chander H; Prasad JP; Anvikar AR; Chand S
    Monoclon Antib Immunodiagn Immunother; 2022 Oct; 41(5):260-274. PubMed ID: 36306517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical Comparison of the Originator Granulocyte-colony Stimulating Factor Filgrastim and its Biosimilars.
    Orlik G; Khan MA; Grieb P
    Curr Pharm Des; 2018; 24(30):3543-3550. PubMed ID: 30417773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cation exchange chromatography on a monodisperse 3 µm particle enables extensive analytical similarity assessment of biosimilars.
    Füssl F; Millán-Martín S; Bones J; Carillo S
    J Pharm Biomed Anal; 2023 Sep; 234():115534. PubMed ID: 37343453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
    Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
    BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.